GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » PB Ratio

Cadrenal Therapeutics (Cadrenal Therapeutics) PB Ratio : 1.07 (As of May. 23, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-23), Cadrenal Therapeutics's share price is $0.4127. Cadrenal Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $0.39. Hence, Cadrenal Therapeutics's PB Ratio of today is 1.07.

The historical rank and industry rank for Cadrenal Therapeutics's PB Ratio or its related term are showing as below:

CVKD' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 8.51
Current: 1.09

During the past 2 years, Cadrenal Therapeutics's highest PB Ratio was 8.51. The lowest was 0.00. And the median was 0.00.

CVKD's PB Ratio is ranked better than
80.35% of 1313 companies
in the Biotechnology industry
Industry Median: 2.54 vs CVKD: 1.09

During the past 12 months, Cadrenal Therapeutics's average Book Value Per Share Growth Rate was 11.50% per year.

Back to Basics: PB Ratio


Cadrenal Therapeutics PB Ratio Historical Data

The historical data trend for Cadrenal Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics PB Ratio Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23
PB Ratio
- 1.25

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only 4.06 5.57 1.01 1.25 1.58

Competitive Comparison of Cadrenal Therapeutics's PB Ratio

For the Biotechnology subindustry, Cadrenal Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadrenal Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadrenal Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cadrenal Therapeutics's PB Ratio falls into.



Cadrenal Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cadrenal Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.4127/0.387
=1.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Cadrenal Therapeutics  (NAS:CVKD) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cadrenal Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadrenal Therapeutics (Cadrenal Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Executives
John Raymond Murphy director 233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham director, 10 percent owner, officer: CEO and Chairman 89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki director C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo officer: Chief Medical Officer 13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske director 120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot officer: Chief Financial Officer 802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson director 2483 NE JULEP STREET, ISSAQUAH WA 98029